Vericel Stock News

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co

The 2021 Biotech Bear market is creating a huge investment opportunity, as fundamentally robust companies are trading at a deep bargain. With its two powerful cellular therapies, Vericel is enjoying s

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on []

Vericel Co. (NASDAQ:VCEL) Investment analysts at Truist Securiti issued their FY2023 EPS estimates for Vericel in a note issued to investors on Tuesday, December 21st. Truist Securiti analyst S. Brodovsky expects that the biotechnology company will earn $0.44 per share for the year. Several other equities analysts also recently commented on VCEL. Zacks Investment []

The post I think Vericel Corp is a buy appeared on BitcoinEthereumNews.com . Penn National Gaming: I like Penn National. I liked it low. I liked it high. I think Penn National is a winner. I think that its done a lot of

"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.

Vericel (NASDAQ:VCEL) had its target price reduced by analysts at Truist Securities from $55.00 to $52.00 in a research note issued on Tuesday, Analyst Ratings Network reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Truist Securities’ target price points to a potential upside of 28.49% from the stock’s current price. […]

New York State Teachers Retirement System increased its stake in shares of Vericel Co. (NASDAQ:VCEL) by 0.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 45,424 shares of the biotechnology companys stock after acquiring an additional 424 shares during the quarter. New York State Teachers Retirement Systems holdings in Vericel were worth $2,217,000 [] The post New York State Teachers Retirement System Buys 424 Shares of Vericel Co. (NASDAQ:VCEL) appeared first on ETF Daily News .

Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Profitability This table compares Titan Pharmaceuticals and Vericels net margins, return on equity and return on [] The post Comparing Titan Pharmaceuticals (NASDAQ:TTNP) and Vericel (NASDAQ:VCEL) appeared first on ETF Daily News .

Analysts expect that Vericel Co. (NASDAQ:VCEL) will announce earnings of $0.20 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vericels earnings, with the lowest EPS estimate coming in at $0.17 and the highest estimate coming in at $0.22. Vericel reported earnings of $0.25 per share during []

Vericel (NASDAQ:VCEL) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Profitability This table compares Vericel and Titan Pharmaceuticals net margins, return on equity and return on []

This global Cartilage Repair/ Cartilage Regeneration market report is the precise depiction of obstructions, drivers or trends that affect the market either positively or negatively. It offers for the scope of other applications that may influence the market situation further.

Perkins Capital Management Inc. reduced its position in shares of Vericel Co. (NASDAQ:VCEL) by 4.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 75,387 shares of the biotechnology companys stock after selling 3,225 shares during the quarter. Vericel accounts for about 2.3% of Perkins Capital Management Inc.s investment portfolio, making the stock []

Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman sold 5,000 shares of the stock in a transaction on Monday, November 29th. The shares were sold at an average price of $39.17, for a total value of $195,850.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Vericel []